idarubicin has been researched along with Aging in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Barbui, T; Bassan, R; Buelli, M; D'Emilio, A; Di Bona, E; Lerede, T; Pogliani, E; Rambaldi, A; Rodeghiero, F; Rossi, G; Viero, P | 1 |
| Adriansson, M; Arheden, K; Axelsson, P; Billström, R; Cervin, A; Fioretos, T; Johansson, B; Mitelman, F; Olofsson, T; Strömbeck, B; Tanke, HJ | 1 |
1 review(s) available for idarubicin and Aging
| Article | Year |
|---|---|
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
3 trial(s) available for idarubicin and Aging
| Article | Year |
|---|---|
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Middle Aged; Outpatients; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Vincristine | 1996 |
2 other study(ies) available for idarubicin and Aging
| Article | Year |
|---|---|
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
Topics: Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Thioguanine | 2001 |